United Therapeutics (UTHR) Enterprise Value (2009 - 2026)

United Therapeutics has disclosed Enterprise Value across 18 years of filings, most recently posting $20.5 billion for Q2 2026.

• In Q2 2026, Enterprise Value rose 105.77% year-over-year to $20.5 billion; the TTM figure through Jun 2026 stood at $20.5 billion (up 105.77% YoY), while the FY2025 annual figure was $18.3 billion, up 46.16% from the prior year.
• Enterprise Value came in at $20.5 billion for Q2 2026 at United Therapeutics, down from $22.8 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $22.8 billion in Q1 2026 to a low of $5.9 billion in Q1 2022.
• Average Enterprise Value over 5 years is $11.3 billion, with a median of $10.0 billion recorded in 2022.
• Year-over-year, Enterprise Value decreased 26.23% in 2023 and jumped 116.04% in 2026.
• Over 5 years, Enterprise Value stood at $10.0 billion in 2022, then declined by 26.23% to $7.3 billion in 2023, then soared by 70.77% to $12.6 billion in 2024, then soared by 46.16% to $18.3 billion in 2025, then increased by 11.54% to $20.5 billion in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $20.5 billion in Q2 2026, $22.8 billion in Q1 2026, and $18.3 billion in Q4 2025.